Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Black Point's Qualifying Transaction With Mistral Pharma Approved by the Shareholders.


MONTREAL -- Black Point Capital Inc. ("Black Point") (TSX TSX Toronto Stock Exchange (TSE before April, 2002)
TSX Transfer from Stack Pointer to Index
TSX True Space Extension
 VENTURE:BPL See broadband over power lines. .P) announced that both its shareholders and the shareholders of Mistral Mis·tral   , Frédéric 1830-1914.

French writer and leader in the revival of Provençal as a literary language. He shared the 1904 Nobel Prize for literature.



mis·tral  
n.
 Pharma Inc. ("Mistral") have approved the amalgamation of Black Point with Mistral at the special meetings held today.

Upon completion of all the formalities, Black Point and Mistral will proceed with the amalgamation. The terms and conditions of the amalgamation are set forth in details in the joint management information circular Information Circular

A document sent to shareholders outlining important matters to be discussed at the annual shareholders' meeting.

Notes:
Sent along with a proxy, the information circular may cover matters such as the election of the Board of Directors, possible
 dated December 17, 2004 pertaining per·tain  
intr.v. per·tained, per·tain·ing, per·tains
1. To have reference; relate: evidence that pertains to the accident.

2.
 to the special meetings of shareholders. The corporation resulting from the amalgamation will be called "Mistral Pharma Inc." and it will carry on the same activities as those currently carried on by Mistral. Mistral's Web site address is www.mistralpharma.com

The amalgamation is conditional upon the issuance of units of Black Point for a minimum amount of $2.5 million and a maximum of $5 million. Each unit will be comprised of one Black Point common share and one Black Point common share purchase warrant. The details of this offering are set forth in the press release issued on December 29, 2204. Canaccord Capital Corporation, First Associates Investments Inc. and Jennings Capital Inc. have agreed to act as agents for this proposed financing.

Black Point also announced that all the other matters submitted to its shareholders were approved including the stock option plan and the amendment of the general by-law.

"Trading in the securities of a capital pool company should be considered highly speculative. The TSX Venture Exchange TSX Venture Exchange

Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors.
 Inc. does not accept responsibility for the adequacy or accuracy of this release."

Black Point Capital Inc. (TSX VENTURE:BPL.P)
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1CANA
Date:Jan 18, 2005
Words:267
Previous Article:DuPont Photomasks to Consolidate Trailing-Edge Production; Company to Close Kokomo, Ind., Facility.
Next Article:Sure Trace Begins Year with New Revenue Contract.
Topics:



Related Articles
Countering the low-level air threat: MANPADS; a handy anti-aircraft missile system for the infantryman.
Matra at Selles St. Denis: a robotized missile den.
Qualifying disposition under regs. sec. 1.1368-1(g): the importance of the form.
RESTAURANT REVISITED: MISTRAL A FLAVORFUL REMINDER.
Black Point Capital Announces Proposed Qualifying Transaction with Mistral Pharma.
Black Point Capital Announces Loan to Mistral Pharma.
Black Point Capital Announces Execution of Amalgamation Agreement with Mistral Pharma and Date of Special Meeting.
Black Point Capital Announces The Filing of a Preliminary Prospectus.
Black Point Capital Announces the Filing of the Final Prospectus.
Dainippon Sumitomo Pharma Announces Launch of "Replagal(R) 3.5 mg" for Anderson-Fabry Disease.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles